FDA Approves AstraZeneca's Imfinzi in Combination with Padcev for Bladder Cancer
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's (AZN) immunotherapy drug, Imfinzi (durvalumab), for use in the perioperative setting to treat muscle-invasive bladder cancer. The approval specifically targets patients who are ineligible for cisplatin-based chemotherapy. The treatment regimen combines Imfinzi with Padcev (enfortumab vedotin), a product developed by Astellas (ALPMY) and Pfizer (PFE). This expansion of the Imfinzi indication represents a significant step in addressing unmet needs for bladder cancer patients who cannot tolerate standard chemotherapy protocols.
Topics: bladder cancer drug combination FDA approval oncology